FibroGen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
11.03.24	FibroGen Appoints Deyaa Adib As CMO (RTTNews)
30.08.23	FibroGen's Pamrevlumab Doesn't Meet Goals In Phase III LELANTOS-2 Trial; Stock Down In Pre-market (RTTNews)
26.06.23	FibroGen: Phase 3 ZEPHYRUS-1 Study Of Pamrevlumab Fails To Meet Endpoints (RTTNews)
18.05.23	FibroGen Announces Positive Data From Phase 3 Study Of Roxadustat For Treatment Of Anemia (RTTNews)
25.08.21	FibroGen Reports Positive Topline Results From Phase 2 Study Of Roxadustat (RTTNews)
20.08.21	Pre-market Movers: GOVX, PROG, SONN, MRIN, NVIV… (RTTNews)
20.08.21	Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease (PR Newswire)
16.07.21	Pre-market Movers: IO, AEHR, DTSS, MRNA, FGEN… (RTTNews)
25.06.21	Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease (PR Newswire)
24.06.21	Biotech Stocks Facing FDA Decision In July 2021 (RTTNews)
11.06.21	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN (PR Newswire)
11.06.21	FIBROGEN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroG... (PR Newswire)
12.04.21	FibroGen: Pamrevlumab Gets FDA's Fast Track Designation To Treat Duchenne Muscular Dystrophy (RTTNews)
02.03.21	AstraZeneca, FibroGen: FDA To Convene Committee Meeting To Review Roxadustat In Anaemia Of CKD (RTTNews)
02.03.21	FDA Says No To ATNX And CRMD, Morphic Jumps On IBD Trial Data, INO's REVEAL 1 Meets Goals (RTTNews)
21.12.20	AstraZeneca Says FDA Extends Review Period Of FibroGen's Anaemia Drug Roxadustat By Three Months (RTTNews)
30.11.20	Biotech Stocks Facing FDA Decision In December 2020 (RTTNews)
27.11.20	Astellas Pharma: Roxadustat Approved In Japan For Adults With Anemia Of CKD Not On Dialysis (RTTNews)
03.09.20	Stock Alert: FibroGen Rises To New 52-week High (RTTNews)
21.05.20	EMA Accepts Astellas' Marketing Authorization Application For Roxadustat (RTTNews)
11.11.19	AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy (RTTNews)
05.11.19	FDA Says "Not Now AVEO", HALO Axes 160 Jobs, RDHL Gets Nod For H.pylori Drug (RTTNews)
20.09.19	Astellas Pharma, FibroGen Announce Approval Of Evrenzo In Japan - Quick Facts (RTTNews)
20.12.18	AstraZeneca & Merck & Co.: SOLO-3 Trial Of Lynparza Demonstrates Positive Result (RTTNews)
18.12.18	AstraZeneca Reports Approval Of Roxadustat In China - Quick Facts (RTTNews)
22.10.18	Week Ahead In Pharmaceuticals: 11 Stocks To Watch (MRTX, EPZM, ITCI...) (RTTNews)
17.10.18	CERS Boosts Revenue Outlook, KOOL Hands Out Pink Slips, EIGR'S UTLRA Study Fails (RTTNews)
13.09.18	ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch (RTTNews)
04.09.18	Is There Still Room To Run For These Biotech Stocks? (RTTNews)
09.11.17	OTIC Data Music To Ears, Apellis IPO Opens Today, CAPR High On HOPE (RTTNews)
16.08.17	ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges (RTTNews)
10.08.17	Biotech Stocks on Investors' Radar -- Dermira, Endocyte, FibroGen, and Global Blood Therapeutics (PR Newswire)
09.08.17	Latest R&D Success, FDA Approvals and Significant Advances in Clinical Trials Boosting Biotech Sector (PR Newswire)
09.08.17	Latest R&D Success, FDA Approvals and Significant Advances in Clinical Trials Boosting Biotech Sector (PR Newswire)
09.08.17	Gainers & Losers Of Aug.8: FGEN, CUTR, ESPR, DEPO, DERM... (RTTNews)
21.07.17	Congress Could Have Major Impact on Biotech Companies (PR Newswire)
21.07.17	Congress Could Have Major Impact on Biotech Companies (PR Newswire)
21.07.17	Congress Could Have Major Impact on Biotech Companies (PR Newswire)
21.07.17	Congress Could Have Major Impact on Biotech Companies (PR Newswire)
22.06.17	FibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer (RTTNews)
17.04.17	How These Biotech Stocks are Faring? -- FibroGen, Bellicum Pharma, Intercept Pharma, and Cellect Biotechnology (PR Newswire)
07.04.17	Gainers & Losers Of Apr.6: HTGM, AKTX, FGEN, ARLZ, ADAP... (RTTNews)
22.02.17	How These Biotech Stocks are Faring? -- Neuralstem, Catalyst Biosciences, Trevena, and FibroGen (PR Newswire)
31.01.17	AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch (RTTNews)
30.01.17	FibroGen's Roxadustat Meets Primary Goals In Two Phase 3 Anemia Studies In China (RTTNews)
20.01.17	Worthy Start of the Year for Biotech Companies (PR Newswire)
01.11.16	ARIA To Face FDA In April, OPXA's Woes Continue, Keep An Eye On OPHT (RTTNews)
07.01.16	Be All Ears For DVAX, QURE, TLOG Disappoints, CCXI Clears Trial (RTTNews)
29.06.15	FibroGen Receives $120 Mn License Payment From AstraZeneca (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu FibroGen Inc

Aktien Top/Flop

Meistgelesene Nachrichten